A Phase 2 interventional study of HL036 ophthalmic solution and Placebo vehicle solution in Dry Eye, sponsored by HanAll BioPharma Co., Ltd.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-07.
Sponsored by HanAll BioPharma Co., Ltd. (part of Daewoong Pharmaceutical Co. LTD.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.
Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 139th largest by enrollment of the 473 interventional ones that give a count, is one of 16 that started in 2017, is one of 97 in phase 2, and was the 249th registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:
Scott & Christie and Associates, PC · Sites in United States
Ages 18+
Bausch & Lomb Incorporated · Sites in United States
Ages 18+
Alcon Research · Sites in United States
Ages 22+ · Healthy volunteers
Cleveland Eye Clinic · Sites in United States
Ages 50–75
Eye Research Associates, LLC · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
544 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 132 · Phase 3 95 · Phase 4 116
First in 1997; this study’s year is marked. 16 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 60 across the 473 interventional studies, 80 across the 64 observational. Of the 439 that completed or were terminated, 232 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
330 of 544 have an industry lead sponsor. The 10 most frequent:
This study is registered under HanAll BioPharma Co., Ltd., one of the names counted as Daewoong Pharmaceutical Co. LTD.. Under that name alone:
HanAll BioPharma Co., Ltd. is the lead sponsor of 16 studies on the registry; none are open to participants now.
Daewoong Pharmaceutical Co. LTD. has 6 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
31 of the studies in Dry Eye Syndromes with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07548632Phase 3OculisA Clinical Study Evaluating Licaminlimab for Dry Eye Disease | 2026-12 |
| NCT07281950Center for Sight Las VegasInvestigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT) | 2026-11-30 |
| NCT07566975Neuro-Ophthalmology of TexasReal-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study | 2026-11-30 |
| NCT07768735Alcon ResearchUNITY DX Cornea Study | 2026-12 |
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 544 studies in Dry Eye Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study was to compare the safety and efficacy of 0.10% and 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants self-administered HL036 0.10 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
Biological: HL036 ophthalmic solution
Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Biological: HL036 ophthalmic solution
Participants self-administered HL036 placebo (vehicle solution) as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
Other: Placebo vehicle solution
HL036 ophthalmic solution
Also known as: Tanfanercept
Placebo vehicle solution
Coprimary Endpoint: Change From Baseline in Inferior Corneal Staining Score to Day 57 (Pre-CAE)
It was evaluated for the inferior region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement.
Time frame: Baseline (Day 1 Pre-CAE), Day 57 (Pre-CAE)
Coprimary Endpoint: Change From Baseline in Ocular Discomfort Score to Day 57 (Pre-CAE)
It is assessed by the Ora Calibra® Ocular Discomfort scale. The score ranged from 0 to 4 (0=none and 4=severe) with 1 point increments, where lower scores indicate improvement.
Time frame: Baseline (Day 1 Pre-CAE), Day 57 (Pre-CAE)
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
It is evaluated for the inferior region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Mean Change From Baseline in Fluorescein Staining (Superior Region)
It is evaluated for the superior region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Mean Change From Baseline in Fluorescein Staining (Central Region)
It is evaluated for the central region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
It is evaluated for the temporal region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
It is evaluated for the nasal region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
Corneal sum score is the sum of all regions of the cornea (inferior, superior and central regions). Individual region score was evaluated on the Ora Calibra® Corneal and Conjunctival staining scale. Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Corneal sum score ranges from 0 to 12. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
Conjunctival sum score is the sum of all regions of the conjunctiva (temporal and nasal regions). Individual region score was evaluated on the Ora Calibra® Corneal and Conjunctival staining scale. Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Conjunctival sum score ranges from 0 to 8. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Total score was sum of all 5 regions: central, superior, inferior, temporal, and nasal. Individual region score was evaluated on the Ora Calibra® Corneal and Conjunctival staining scale. Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 20. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Mean Change From Baseline in Lissamine Green Staining Total Score (Inferior Region)
It is evaluated for the inferior region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Mean Change From Baseline in Lissamine Green Staining Total Score (Superior Region)
It is evaluated for the superior region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Mean Change From Baseline in Lissamine Green Staining Total Score (Central Region)
It is evaluated for the central region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Mean Change From Baseline in Lissamine Green Staining Total Score (Temporal Region)
It is evaluated for the temporal region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Mean Change From Baseline in Lissamine Green Staining Total Score (Nasal Region)
It is evaluated for the nasal region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Mean Change From Baseline in Lissamine Green Staining Total Score (Corneal Sum)
Corneal sum score is the sum of all regions of the cornea (inferior, superior and central regions). Individual region score was evaluated on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 12. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Mean Change From Baseline in Lissamine Green Staining Total Score (Conjunctival Sum)
Conjunctival sum score is the sum of all regions of the conjunctiva (temporal and nasal regions). Individual region score was evaluated on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 8. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
Total score was sum of all 5 regions: central, superior, inferior, temporal, and nasal. Individual region score was evaluated on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 20. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Change From Baseline in Tear Film Break-Up Time
Sodium fluorescein solution was instilled into each eye and participants were instructed to blinked several times. The time it takes to form micelles from the time that the eye is opened was noted.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
It is evaluated by the Ora Calibra® conjunctival redness scale for dry eye. The score ranges from 0 to 4 (0=none and 4=severe), where lower score indicates improvement
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Change From Baseline in Schirmer's Test
The Schirmer test strip will be placed in the lower temporal lid margin of each eye. Subjects will be instructed to close their eyes and After 5 minutes have elapsed, The length of moistened area of schirmer strip will be recorded (mm) for each eye.
Time frame: Baseline (Day 1); Days 15, 29, and 57
Change From Baseline in Ora Calibra® Ocular Discomfort Scale
It was assessed by the Ora Calibra® ocular discomfort scale. The score ranges from 0 to 4 (0=none and 4=severe), where lower score indicates improvement.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of overall ocular discomfort at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of burning at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of dryness at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of grittiness at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of stinging at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Change From Baseline in Visual Analog Scale (Burning)
Participants rated ocular symptom of burning by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Change From Baseline in Visual Analog Scale (Itching)
Participants rated ocular symptom of itching by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Change From Baseline in Visual Analog Scale (Foreign Body)
Participants rated ocular symptom of foreign body by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Change From Baseline in Visual Analog Scale (Blurred Vision)
Participants rated ocular symptom of blurred vision by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Change From Baseline in Visual Analog Scale (Dryness)
Participants rated ocular symptom of dryness by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Change From Baseline in Visual Analog Scale (Photophobia)
Participants rated ocular symptom of photophobia by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Change From Baseline in Visual Analog Scale (Pain)
Participants rated ocular symptom of pain by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."
Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Change From Baseline in Ocular Surface and Disease Index (OSDI©)
The OSDI is a simple 12-question survey that rates the severity of the participant's dry eye disease based on the symptoms. It is assessed on a scale of 0 to 100, with higher score representing greater disability.
Time frame: Baseline (Day 1); Days 8, 15, 29, and 57
Ora Calibra® Drop Comfort Scale
Ora Calibra® drop comfort scale ranges from 0 to 10. A score of 0 indicates comfortable and 10 indicates uncomfortable. Lower score indicated better comfort level.
Time frame: Upon instillation and 1 and 2 minutes post-instillation on Day 1
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of overall ocular discomfort twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.
Time frame: From Baseline (Day 1) to Day 56
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of burning twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.
Time frame: From Baseline (Day 1) to Day 56
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of dryness twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.
Time frame: From Baseline (Day 1) to Day 56
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of grittiness twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.
Time frame: From Baseline (Day 1) to Day 56
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of stinging twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.
Time frame: From Baseline (Day 1) to Day 56
Participants who met all the eligibility criteria were enrolled at 2 sites in the United States.
| Milestone | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Started | 50 | 50 | 50 |
| Completed | 46 | 43 | 49 |
| Not completed | 4 | 7 | 1 |
| Withdrew: Adverse event | 3 | 5 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 |
| Withdrew: Administrative reasons | 1 | 0 | 0 |
| Withdrew: Hypertension not controlled | 0 | 1 | 0 |
It was evaluated for the inferior region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 1.94 ± 0.512 | 1.96 ± 0.450 | 1.95 ± 0.433 |
| Change From Baseline to Day 57 (pre-CAE) | 0.10 ± 0.699 | 0.10 ± 0.490 | -0.02 ± 0.631 |
It is assessed by the Ora Calibra® Ocular Discomfort scale. The score ranged from 0 to 4 (0=none and 4=severe) with 1 point increments, where lower scores indicate improvement.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 2.6 ± 0.86 | 2.5 ± 0.95 | 2.4 ± 0.75 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.5 ± 1.16 | -0.4 ± 1.33 | -0.1 ± 0.88 |
It is evaluated for the inferior region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 1.94 ± 0.512 | 1.96 ± 0.450 | 1.95 ± 0.443 |
| Day 1 Post-CAE | 3.32 ± 0.492 | 3.25 ± 0.565 | 3.20 ± 0.474 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 1.38 ± 0.521 | 1.29 ± 0.464 | 1.25 ± 0.407 |
| Change from Baseline: Day 8 | 0.19 ± 0.706 | -0.01 ± 0.606 | 0.04 ± 0.668 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.12 ± 0.697 | -0.20 ± 0.608 | -0.10 ± 0.571 |
| Change from Baseline: Day 15 (Post-CAE) | -0.62 ± 0.766 | -0.85 ± 0.736 | -0.69 ± 0.826 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -0.50 ± 0.892 | -0.66 ± 0.793 | -0.59 ± 0.867 |
| Change from Baseline: Day 29 (Pre-CAE) | 0.04 ± 0.807 | 0.04 ± 0.563 | 0.00 ± 0.707 |
| Change from Baseline: Day 29 (Post-CAE) | -0.41 ± 0.656 | -0.83 ± 0.677 | -0.48 ± 0.569 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -0.66 ± 0.857 | -1.02 ± 0.624 | -0.64 ± 0.591 |
| Change from Baseline: Day 57 (Pre-CAE) | 0.12 ± 0.724 | 0.10 ± 0.512 | -0.02 ± 0.631 |
| Change from Baseline: Day 57 (Post-CAE) | -0.47 ± 0.670 | -0.84 ± 0.738 | -0.63 ± 0.610 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -0.59 ± 0.878 | -0.92 ± 0.663 | -0.62 ± 0.747 |
It is evaluated for the superior region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 2.05 ± 0.420 | 2.08 ± 0.444 | 2.03 ± 0.456 |
| Day 1 Post-CAE | 2.69 ± 0.552 | 2.56 ± 0.559 | 2.45 ± 0.556 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 0.64 ± 0.598 | 0.48 ± 0.622 | 0.42 ± 0.650 |
| Change from Baseline: Day 8 | -0.09 ± 0.586 | -0.27 ± 0.592 | -0.09 ± 0.556 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.22 ± 0.790 | -0.45 ± 0.724 | -0.29 ± 0.615 |
| Change from Baseline: Day 15 (Post-CAE) | -0.66 ± 0.976 | -0.72 ± 0.798 | -0.34 ± 0.658 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -0.44 ± 0.884 | -0.27 ± 0.743 | -0.05 ± 0.791 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.27 ± 0.709 | -0.25 ± 0.555 | -0.10 ± 0.707 |
| Change from Baseline: Day 29 (Post-CAE) | -0.50 ± 0.655 | -0.65 ± 0.822 | -0.07 ± 0.604 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -0.41 ± 0.791 | -0.52 ± 0.964 | -0.09 ± 0.782 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.09 ± 0.571 | -0.14 ± 0.594 | -0.19 ± 0.713 |
| Change from Baseline: Day 57 (Post-CAE) | -0.46 ± 0.665 | -0.37 ± 0.787 | -0.23 ± 0.662 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -0.37 ± 0.806 | -0.21 ± 0.847 | -0.08 ± 0.915 |
It is evaluated for the central region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 1.45 ± 0.687 | 1.57 ± 0.670 | 1.49 ± 0.610 |
| Day 1 Post-CAE | 2.22 ± 0.624 | 2.09 ± 0.550 | 2.04 ± 0.676 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 0.77 ± 0.641 | 0.052 ± 0.735 | 0.55 ± 0.633 |
| Change from Baseline: Day 8 | 0.12 ± 0.766 | -0.02 ± 0.887 | -0.05 ± 0.779 |
| Change from Baseline: Day 15 (Pre-CAE) | 0.00 ± 0.869 | -0.24 ± 0.831 | -0.09 ± 0.780 |
| Change from Baseline: Day 15 (Post-CAE) | -0.52 ± 0.749 | -0.58 ± 0.732 | -0.42 ± 0.724 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -0.52 ± 0.963 | -0.34 ± 0.923 | -0.33 ± 0.956 |
| Change from Baseline: Day 29 (Pre-CAE) | 0.01 ± 0.906 | -0.21 ± 0.771 | -0.07 ± 0.776 |
| Change from Baseline: Day 29 (Post-CAE) | -0.50 ± 0.612 | -0.54 ± 0.528 | -0.16 ± 0.653 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -0.69 ± 0.870 | -0.54 ± 0.948 | -0.20 ± 0.916 |
| Change from Baseline: Day 57 (Pre-CAE) | 0.00 ± 0.837 | -0.10 ± 0.832 | -0.20 ± 0.802 |
| Change from Baseline: Day 57 (Post-CAE) | -0.36 ± 0.765 | -0.35 ± 0.856 | -0.30 ± 0.847 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -0.36 ± 1.089 | -0.23 ± 1.043 | -0.13 ± 0.846 |
It is evaluated for the temporal region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 2.14 ± 0.452 | 2.12 ± 0.521 | 2.02 ± 0.622 |
| Day 1 Post-CAE | 2.60 ± 0.606 | 2.42 ± 0.538 | 2.47 ± 0.519 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 0.46 ± 0.523 | 0.30 ± 0.647 | 0.45 ± 0.625 |
| Change from Baseline: Day 8 | -0.01 ± 0.520 | -0.09 ± 0.598 | -0.13 ± 0.755 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.34 ± 0.601 | -0.31 ± 0.741 | -0.14 ± 0.736 |
| Change from Baseline: Day 15 (Post-CAE) | -0.49 ± 0.739 | -0.54 ± 0.683 | -0.54 ± 0.552 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -0.15 ± 0.835 | -0.23 ± 0.765 | -0.40 ± 0.857 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.19 ± 0.706 | -0.18 ± 0.828 | -0.10 ± 0.714 |
| Change from Baseline: Day 29 (Post-CAE) | -0.34 ± 0.569 | -0.38 ± 0.653 | -0.20 ± 0.478 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -0.26 ± 0.872 | -0.33 ± 0.894 | -0.20 ± 0.737 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.07 ± 0.554 | 0.06 ± 0.749 | -0.09 ± 0.754 |
| Change from Baseline: Day 57 (Post-CAE) | -0.30 ± 0.679 | -0.24 ± 0.767 | -0.33 ± 0.696 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -0.24 ± 0.842 | -0.28 ± 0.902 | -0.26 ± 0.824 |
It is evaluated for the nasal region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 2.27 ± 0.507 | 2.26 ± 0.527 | 2.14 ± 0.544 |
| Day 1 Post-CAE | 2.74 ± 0.649 | 2.67 ± 0.577 | 2.68 ± 0.587 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 0.47 ± 0.557 | 0.41 ± 0.541 | 0.54 ± 0.638 |
| Change from Baseline: Day 8 | -0.06 ± 0.501 | -0.05 ± 0.518 | -0.05 ± 0.702 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.28 ± 0.743 | -0.29 ± 0.600 | -0.06 ± 0.620 |
| Change from Baseline: Day 15 (Post-CAE) | -0.44 ± 0.697 | -0.52 ± 0.785 | -0.51 ± 0.773 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -0.16 ± 0.830 | -0.23 ± 0.772 | -0.45 ± 0.859 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.20 ± 0.735 | -0.18 ± 0.688 | -0.04 ± 0.783 |
| Change from Baseline: Day 29 (Post-CAE) | -0.17 ± 0.658 | -0.19 ± 0.694 | -0.20 ± 0.643 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -0.03 ± 0.755 | -0.06 ± 0.589 | -0.17 ± 0.877 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.01 ± 0.771 | 0.01 ± 0.678 | -0.24 ± 0.600 |
| Change from Baseline: Day 57 (Post-CAE) | -0.29 ± 0.671 | -0.26 ± 0.960 | -0.38 ± 0.718 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -0.28 ± 0.696 | -0.27 ± 0.928 | -0.15 ± 0.805 |
Corneal sum score is the sum of all regions of the cornea (inferior, superior and central regions). Individual region score was evaluated on the Ora Calibra® Corneal and Conjunctival staining scale. Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Corneal sum score ranges from 0 to 12. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 5.44 ± 1.232 | 5.61 ± 1.230 | 5.47 ± 1.154 |
| Day 1 Post-CAE | 8.23 ± 1.318 | 7.90 ± 1.241 | 7.69 ± 1.340 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 2.79 ± 1.258 | 2.29 ± 1.246 | 2.22 ± 1.135 |
| Change from Baseline: Day 8 | 0.22 ± 1.559 | -0.30 ± 1.584 | -0.10 ± 1.544 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.34 ± 1.939 | -0.89 ± 1.562 | -0.48 ± 1.474 |
| Change from Baseline: Day 15 (Post-CAE) | -1.80 ± 2.058 | -2.16 ± 1.695 | -1.45 ± 1.526 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -1.46 ± 1.935 | -1.27 ± 1.516 | -0.97 ± 1.739 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.22 ± 1.995 | -0.42 ± 1.404 | -0.17 ± 1.704 |
| Change from Baseline: Day 29 (Post-CAE) | -1.41 ± 1.389 | -2.02 ± 1.360 | -0.71 ± 1.205 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -1.76 ± 1.850 | -2.08 ± 1.659 | -0.93 ± 1.438 |
| Change from Baseline: Day 57 (Pre-CAE) | 0.03 ± 1.470 | -0.14 ± 1.579 | -0.41 ± 1.634 |
| Change from Baseline: Day 57 (Post-CAE) | -1.28 ± 1.618 | -1.56 ± 1.780 | -1.16 ± 1.748 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -1.32 ± 2.034 | -1.36 ± 1.881 | -0.84 ± 1.801 |
Conjunctival sum score is the sum of all regions of the conjunctiva (temporal and nasal regions). Individual region score was evaluated on the Ora Calibra® Corneal and Conjunctival staining scale. Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Conjunctival sum score ranges from 0 to 8. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 4.41 ± 0.879 | 4.38 ± 0.923 | 4.16 ± 1.052 |
| Day 1 Post-CAE | 5.34 ± 1.118 | 5.09 ± 0.941 | 5.15 ± 0.981 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 0.93 ± 0.827 | 0.71 ± 0.964 | 0.99 ± 1.095 |
| Change from Baseline: Day 8 | -0.07 ± 0.845 | -0.15 ± 0.875 | -0.18 ± 1.349 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.62 ± 1.167 | -0.60 ± 1.158 | -0.20 ± 1.143 |
| Change from Baseline: Day 15 (Post-CAE) | -0.93 ± 1.212 | -1.06 ± 1.295 | -1.05 ± 1.135 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -0.31 ± 1.269 | -0.46 ± 1.258 | -0.85 ± 1.440 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.39 ± 1.263 | -0.35 ± 1.360 | -0.14 ± 1.327 |
| Change from Baseline: Day 29 (Post-CAE) | -0.52 ± 0.986 | -0.58 ± 1.206 | -0.39 ± 0.927 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -0.29 ± 1.379 | -0.38 ± 1.219 | -0.37 ± 1.377 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.08 ± 1.178 | 0.07 ± 1.269 | -0.33 ± 1.223 |
| Change from Baseline: Day 57 (Post-CAE) | -0.60 ± 1.177 | -0.50 ± 1.528 | -0.70 ± 1.194 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -0.52 ± 1.273 | -0.55 ± 1.573 | -0.41 ± 1.306 |
Total score was sum of all 5 regions: central, superior, inferior, temporal, and nasal. Individual region score was evaluated on the Ora Calibra® Corneal and Conjunctival staining scale. Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 20. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 9.85 ± 1.852 | 9.99 ± 1.777 | 9.63 ± 1.982 |
| Day 1 Post-CAE | 13.57 ± 2.143 | 12.99 ± 1.828 | 12.84 ± 1.872 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 3.72 ± 1.614 | 3.00 ± 1.684 | 3.21 ± 1.890 |
| Change from Baseline: Day 8 | 0.15 ± 2.139 | -0.45 ± 2.009 | -0.29 ± 2.667 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.96 ± 2.866 | -1.49 ± 2.312 | -0.68 ± 2.338 |
| Change from Baseline: Day 15 (Post-CAE) | -2.73 ± 2.875 | -3.22 ± 2.664 | -2.50 ± 2.150 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -1.77 ± 2.686 | -1.73 ± 2.245 | -1.82 ± 2.676 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.61 ± 2.933 | -0.77 ± 2.214 | -0.30 ± 2.710 |
| Change from Baseline: Day 29 (Post-CAE) | -1.93 ± 1.831 | -2.60 ± 2.168 | -1.11 ± 1.739 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -2.05 ± 2.530 | -2.46 ± 2.054 | -1.30 ± 2.403 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.04 ± 2.250 | -0.07 ± 2.403 | -0.74 ± 2.560 |
| Change from Baseline: Day 57 (Post-CAE) | -1.88 ± 2.400 | -2.06 ± 2.990 | -1.87 ± 2.559 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -1.84 ± 2.763 | -1.91 ± 2.922 | -1.24 ± 2.387 |
It is evaluated for the inferior region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 1.42 ± 0.642 | 1.46 ± 0.605 | 1.50 ± 0.580 |
| Day 1 Post-CAE | 2.00 ± 0.920 | 2.12 ± 0.895 | 1.87 ± 0.826 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 0.58 ± 0.752 | 0.66 ± 0.934 | 0.37 ± 0.850 |
| Change from Baseline: Day 8 | 0.04 ± 0.699 | -0.30 ± 0.642 | -0.08 ± 0.702 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.34 ± 0.805 | -0.43 ± 0.644 | -0.48 ± 0.707 |
| Change from Baseline: Day 15 (Post-CAE) | -0.46 ± 1.228 | -0.76 ± 0.984 | -0.34 ± 1.104 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -0.12 ± 0.982 | -0.33 ± 0.919 | 0.14 ± 1.170 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.14 ± 0.815 | -0.24 ± 0.715 | -0.28 ± 0.607 |
| Change from Baseline: Day 29 (Post-CAE) | -0.10 ± 1.191 | -0.69 ± 0.895 | -0.20 ± 1.074 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -0.10 ± 1.064 | -0.60 ± 0.949 | 0.16 ± 1.147 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.21 ± 0.637 | -0.17 ± 0.869 | -0.34 ± 0.688 |
| Change from Baseline: Day 57 (Post-CAE) | -0.16 ± 0.943 | -0.60 ± 0.877 | -0.22 ± 0.764 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | 0.04 ± 0.881 | -0.38 ± 1.179 | 0.07 ± 0.866 |
It is evaluated for the superior region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 1.22 ± 0.507 | 1.32 ± 0.560 | 1.27 ± 0.546 |
| Day 1 Post-CAE | 1.48 ± 0.580 | 1.51 ± 0.703 | 1.44 ± 0.697 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 0.26 ± 0.527 | 0.19 ± 0.669 | 0.17 ± 0.760 |
| Change from Baseline: Day 8 | -0.14 ± 0.525 | -0.31 ± 0.624 | -0.18 ± 0.537 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.37 ± 0.838 | -0.57 ± 0.772 | -0.38 ± 0.907 |
| Change from Baseline: Day 15 (Post-CAE) | -0.48 ± 0.931 | -0.66 ± 0.870 | -0.34 ± 0.866 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -0.11 ± 0.841 | -0.08 ± 0.808 | 0.04 ± 0.936 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.29 ± 0.729 | -0.33 ± 0.604 | -0.44 ± 0.712 |
| Change from Baseline: Day 29 (Post-CAE) | -0.19 ± 0.806 | -0.31 ± 0.849 | 0.02 ± 0.713 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -0.14 ± 0.789 | -0.04 ± 0.916 | 0.30 ± 0.896 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.32 ± 0.541 | -0.36 ± 0.694 | -0.40 ± 0.769 |
| Change from Baseline: Day 57 (Post-CAE) | -0.37 ± 0.679 | -0.44 ± 0.717 | -0.28 ± 0.736 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -0.05 ± 0.797 | -0.05 ± 0.762 | 0.08 ± 0.915 |
It is evaluated for the central region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 0.48 ± 0.735 | 0.57 ± 0.742 | 0.54 ± 0.734 |
| Day 1 Post-CAE | 0.59 ± 0.780 | 0.60 ± 0.735 | 0.66 ± 0.823 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 0.11 ± 0.547 | 0.03 ± 0.519 | 0.12 ± 0.799 |
| Change from Baseline: Day 8 | -0.13 ± 0.676 | -0.29 ± 0.582 | -0.24 ± 0.723 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.13 ± 0.720 | -0.26 ± 0.636 | -0.24 ± 0.744 |
| Change from Baseline: Day 15 (Post-CAE) | -0.33 ± 0.636 | -0.29 ± 0.706 | -0.30 ± 0.647 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -0.20 ± 0.776 | -0.03 ± 0.815 | -0.06 ± 0.935 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.31 ± 0.630 | -0.22 ± 0.837 | -0.28 ± 0.730 |
| Change from Baseline: Day 29 (Post-CAE) | -0.07 ± 0.258 | -0.15 ± 0.660 | -0.07 ± 0.466 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | 0.03 ± 0.680 | -0.17 ± 0.677 | 0.11 ± 0.956 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.23 ± 0.555 | -0.31 ± 0.667 | -0.16 ± 0.681 |
| Change from Baseline: Day 57 (Post-CAE) | -0.14 ± 0.602 | -0.34 ± 0.898 | -0.31 ± 0.619 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | 0.09 ± 0.652 | -0.02 ± 0.879 | -0.18 ± 0.782 |
It is evaluated for the temporal region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 1.63 ± 0.706 | 1.63 ± 0.669 | 1.61 ± 0.751 |
| Day 1 Post-CAE | 1.87 ± 0.691 | 1.71 ± 0.671 | 1.87 ± 0.734 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 0.24 ± 0.649 | 0.08 ± 0.695 | 0.26 ± 0.834 |
| Change from Baseline: Day 8 | -0.09 ± 0.733 | -0.11 ± 0.864 | -0.15 ± 0.686 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.32 ± 0.885 | -0.48 ± 0.707 | -0.46 ± 0.885 |
| Change from Baseline: Day 15 (Post-CAE) | -0.37 ± 0.669 | -0.50 ± 0.772 | -0.50 ± 0.606 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -0.05 ± 0.876 | -0.02 ± 0.928 | -0.04 ± 0.919 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.29 ± 0.915 | -0.21 ± 0.683 | -0.19 ± 0.630 |
| Change from Baseline: Day 29 (Post-CAE) | -0.28 ± 0.663 | -0.06 ± 0.668 | -0.25 ± 0.569 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -0.09 ± 1.142 | 0.08 ± 0.688 | -0.05 ± 0.916 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.26 ± 0.721 | -0.20 ± 0.816 | -0.16 ± 0.710 |
| Change from Baseline: Day 57 (Post-CAE) | -0.21 ± 0.750 | -0.22 ± 0.934 | -0.22 ± 0.715 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | 0.05 ± 1.029 | 0.03 ± 0.947 | -0.07 ± 1.066 |
It is evaluated for the nasal region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 1.90 ± 0.707 | 1.96 ± 0.561 | 1.69 ± 0.638 |
| Day 1 Post-CAE | 2.18 ± 0.774 | 2.05 ± 0.828 | 1.93 ± 0.693 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 0.28 ± 0.640 | 0.09 ± 0.740 | 0.24 ± 0.816 |
| Change from Baseline: Day 8 | -0.04 ± 0.748 | -0.25 ± 0.668 | 0.00 ± 0.677 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.22 ± 0.723 | -0.48 ± 0.660 | -0.23 ± 0.822 |
| Change from Baseline: Day 15 (Post-CAE) | -0.23 ± 0.858 | -0.29 ± 0.904 | -0.24 ± 0.672 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -0.01 ± 0.901 | 0.19 ± 1.070 | -0.01 ± 1.013 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.28 ± 0.679 | -0.39 ± 0.638 | -0.03 ± 0.785 |
| Change from Baseline: Day 29 (Post-CAE) | -0.19 ± 0.737 | 0.10 ± 0.749 | -0.11 ± 0.854 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | 0.09 ± 0.780 | 0.52 ± 0.781 | -0.02 ± 1.004 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.12 ± 0.709 | -0.31 ± 0.692 | -0.10 ± 0.721 |
| Change from Baseline: Day 57 (Post-CAE) | -0.26 ± 0.815 | -0.16 ± 0.843 | -0.02 ± 0.841 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -0.14 ± 0.821 | 0.17 ± 0.872 | 0.05 ± 0.959 |
Corneal sum score is the sum of all regions of the cornea (inferior, superior and central regions). Individual region score was evaluated on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 12. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 3.12 ± 1.272 | 3.35 ± 1.360 | 3.31 ± 1.344 |
| Day 1 Post-CAE | 4.07 ± 1.705 | 4.23 ± 1.785 | 3.97 ± 1.828 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 0.95 ± 1.314 | 0.88 ± 1.683 | 0.66 ± 1.701 |
| Change from Baseline: Day 8 | -0.23 ± 1.258 | -0.91 ± 1.382 | -0.51 ± 1.375 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.84 ± 1.633 | -1.26 ± 1.568 | -1.10 ± 1.909 |
| Change from Baseline: Day 15 (Post-CAE) | -1.27 ± 2.264 | -1.71 ± 2.118 | -0.98 ± 1.924 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -0.43 ± 1.648 | -0.45 ± 1.952 | 0.12 ± 1.965 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.74 ± 1.516 | -0.79 ± 1.487 | -1.00 ± 1.488 |
| Change from Baseline: Day 29 (Post-CAE) | -0.36 ± 1.782 | -1.15 ± 1.754 | -0.25 ± 1.430 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -0.21 ± 1.578 | -0.81 ± 1.588 | 0.57 ± 1.783 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.75 ± 1.228 | -0.84 ± 1.751 | -0.90 ± 1.793 |
| Change from Baseline: Day 57 (Post-CAE) | -0.67 ± 1.674 | -1.38 ± 1.936 | -0.81 ± 1.439 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | 0.08 ± 1.494 | -0.45 ± 2.154 | -0.03 ± 1.586 |
Conjunctival sum score is the sum of all regions of the conjunctiva (temporal and nasal regions). Individual region score was evaluated on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 8. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 3.53 ± 1.231 | 3.59 ± 1.058 | 3.30 ± 1.237 |
| Day 1 Post-CAE | 4.05 ± 1.314 | 3.76 ± 1.322 | 3.80 ± 1.262 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 0.52 ± 1.092 | 0.17 ± 1.223 | 0.50 ± 1.403 |
| Change from Baseline: Day 8 | -0.13 ± 1.249 | -0.36 ± 1.197 | -0.15 ± 1.133 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.54 ± 1.417 | -0.96 ± 1.056 | -0.69 ± 1.548 |
| Change from Baseline: Day 15 (Post-CAE) | -0.60 ± 1.245 | -0.79 ± 1.228 | -0.74 ± 1.084 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -0.06 ± 1.427 | 0.17 ± 1.524 | -0.05 ± 1.724 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.57 ± 1.336 | -0.59 ± 1.090 | -0.22 ± 1.112 |
| Change from Baseline: Day 29 (Post-CAE) | -0.47 ± 1.195 | 0.04 ± 1.264 | -0.36 ± 1.154 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | 0.00 ± 1.553 | 0.60 ± 1.200 | -0.07 ± 1.412 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.38 ± 1.175 | -0.51 ± 1.349 | -0.26 ± 1.222 |
| Change from Baseline: Day 57 (Post-CAE) | -0.47 ± 1.356 | -0.38 ± 1.577 | -0.24 ± 1.377 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -0.09 ± 1.668 | 0.21 ± 1.461 | -0.02 ± 1.723 |
Total score was sum of all 5 regions: central, superior, inferior, temporal, and nasal. Individual region score was evaluated on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 20. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 6.65 ± 2.277 | 6.94 ± 2.091 | 6.61 ± 2.223 |
| Day 1 Post-CAE | 8.12 ± 2.653 | 7.99 ± 2.753 | 7.77 ± 2.741 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 1.47 ± 1.923 | 1.05 ± 2.493 | 1.16 ± 2.708 |
| Change from Baseline: Day 8 | -0.36 ± 2.124 | -1.27 ± 2.065 | -0.66 ± 2.090 |
| Change from Baseline: Day 15 (Pre-CAE) | -1.38 ± 2.767 | -2.22 ± 2.193 | -1.79 ± 3.059 |
| Change from Baseline: Day 15 (Post-CAE) | -1.87 ± 3.156 | -2.50 ± 2.836 | -1.72 ± 2.607 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -0.49 ± 2.409 | -0.28 ± 2.633 | 0.07 ± 3.161 |
| Change from Baseline: Day 29 (Pre-CAE) | -1.31 ± 2.435 | -1.39 ± 2.038 | -1.22 ± 2.150 |
| Change from Baseline: Day 29 (Post-CAE) | -0.83 ± 2.369 | -1.12 ± 2.455 | -0.61 ± 2.025 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -0.21 ± 2.551 | -0.21 ± 2.016 | 0.50 ± 2.553 |
| Change from Baseline: Day 57 (Pre-CAE) | -1.13 ± 1.815 | -1.35 ± 2.684 | -1.16 ± 2.616 |
| Change from Baseline: Day 57 (Post-CAE) | -1.14 ± 2.635 | -1.77 ± 3.087 | -1.05 ± 2.424 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -0.01 ± 2.568 | -0.24 ± 3.138 | -0.05 ± 2.716 |
Sodium fluorescein solution was instilled into each eye and participants were instructed to blinked several times. The time it takes to form micelles from the time that the eye is opened was noted.
| seconds | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 1.559 ± 0.5031 | 1.709 ± 0.7083 | 1.574 ± 0.5394 |
| Day 1 Post-CAE | 1.533 ± 0.5217 | 1.555 ± 0.5441 | 1.574 ± 0.5322 |
| Day 1 (Change from Pre-CAE to Post-CAE) | -0.027 ± 0.4552 | -0.154 ± 0.5516 | -0.001 ± 0.3670 |
| Change from Baseline: Day 8 | 0.024 ± 0.4943 | -0.037 ± 0.7421 | -0.036 ± 0.4948 |
| Change from Baseline: Day 15 (Pre-CAE) | 0.386 ± 0.8008 | 0.127 ± 0.7945 | 0.276 ± 0.7857 |
| Change from Baseline: Day 15 (Post-CAE) | 0.312 ± 0.9470 | 0.195 ± 0.6835 | 0.222 ± 0.7884 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -0.075 ± 0.7355 | 0.068 ± 0.6543 | -0.054 ± 0.6252 |
| Change from Baseline: Day 29 (Pre-CAE) | 0.218 ± 0.7586 | -0.191 ± 0.5936 | -0.077 ± 0.5228 |
| Change from Baseline: Day 29 (Post-CAE) | 0.123 ± 0.7116 | 0.086 ± 0.6752 | -0.188 ± 0.3884 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -0.054 ± 0.5013 | 0.129 ± 0.4258 | -0.119 ± 0.5623 |
| Change from Baseline: Day 57 (Pre-CAE) | 0.139 ± 0.5727 | -0.036 ± 0.8880 | 0.186 ± 0.6696 |
| Change from Baseline: Day 57 (Post-CAE) | 0.118 ± 0.7072 | 0.039 ± 0.6057 | 0.160 ± 0.7206 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -0.021 ± 0.6113 | 0.063 ± 0.8557 | -0.003 ± 0.6473 |
It is evaluated by the Ora Calibra® conjunctival redness scale for dry eye. The score ranges from 0 to 4 (0=none and 4=severe), where lower score indicates improvement
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 1.70 ± 0.639 | 1.66 ± 0.566 | 1.72 ± 0.536 |
| Day 1 Post-CAE | 2.03 ± 0.626 | 2.02 ± 0.571 | 2.04 ± 0.523 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 0.33 ± 0.603 | 0.36 ± 0.655 | 0.32 ± 0.569 |
| Change from Baseline: Day 8 | 0.04 ± 0.588 | -0.07 ± 0.473 | 0.00 ± 0.669 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.20 ± 0.606 | -0.17 ± 0.559 | -0.17 ± 0.568 |
| Change from Baseline: Day 15 (Post-CAE) | -0.14 ± 0.663 | -0.35 ± 0.515 | -0.20 ± 0.606 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | 0.06 ± 0.983 | -0.19 ± 0.836 | -0.03 ± 0.785 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.06 ± 0.740 | -0.03 ± 0.614 | -0.10 ± 0.685 |
| Change from Baseline: Day 29 (Post-CAE) | -0.22 ± 0.635 | -0.31 ± 0.601 | -0.21 ± 0.568 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -0.05 ± 0.967 | -0.21 ± 0.907 | -0.11 ± 1.012 |
| Change from Baseline: Day 57 (Pre-CAE) | 0.01 ± 0.563 | 0.23 ± 0.660 | 0.11 ± 0.565 |
| Change from Baseline: Day 57 (Post-CAE) | -0.03 ± 0.591 | -0.01 ± 0.728 | -0.14 ± 0.586 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -0.04 ± 0.788 | -0.22 ± 0.941 | -0.28 ± 0.708 |
The Schirmer test strip will be placed in the lower temporal lid margin of each eye. Subjects will be instructed to close their eyes and After 5 minutes have elapsed, The length of moistened area of schirmer strip will be recorded (mm) for each eye.
| mm | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 | 5.0 ± 2.60 | 5.2 ± 3.03 | 5.5 ± 3.02 |
| Change From Baseline: Day 15 | 1.7 ± 5.21 | 4.0 ± 7.36 | 3.4 ± 6.50 |
| Change From Baseline: Day 29 | 0.8 ± 5.01 | 0.9 ± 4.23 | 1.8 ± 4.35 |
| Change From Baseline: Day 57 | 3.5 ± 6.70 | 2.9 ± 4.74 | 3.3 ± 6.84 |
It was assessed by the Ora Calibra® ocular discomfort scale. The score ranges from 0 to 4 (0=none and 4=severe), where lower score indicates improvement.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 2.6 ± 0.86 | 2.5 ± 0.95 | 2.4 ± 0.75 |
| Day 1 Post-CAE | 3.8 ± 0.52 | 3.7 ± 0.47 | 3.8 ± 0.52 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 1.2 ± 0.98 | 1.2 ± 1.01 | 1.4 ± 0.81 |
| Change from Baseline: Day 8 | -0.5 ± 0.89 | 0.1 ± 0.81 | -0.1 ± 1.01 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.5 ± 0.71 | -0.1 ± 0.96 | -0.1 ± 0.87 |
| Change from Baseline: Day 15 (Post-CAE) | 0.0 ± 0.62 | 0.0 ± 0.58 | 0.0 ± 0.55 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | 0.5 ± 0.91 | 0.1 ± 1.13 | 0.1 ± 1.05 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.4 ± 1.03 | -0.3 ± 0.92 | -0.2 ± 1.05 |
| Change from Baseline: Day 29 (Post-CAE) | 0.0 ± 0.63 | -0.2 ± 0.63 | 0.0 ± 0.88 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | 0.5 ± 1.18 | 0.0 ± 1.11 | 0.1 ± 1.36 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.5 ± 1.17 | -0.4 ± 1.39 | -0.1 ± 0.88 |
| Change from Baseline: Day 57 (Post-CAE) | -0.2 ± 0.77 | -0.1 ± 0.65 | -0.2 ± 0.76 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | 0.3 ± 1.30 | 0.4 ± 1.43 | -0.1 ± 1.17 |
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of overall ocular discomfort at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 2.9 ± 0.88 | 2.7 ± 1.09 | 2.8 ± 0.78 |
| Day 1 Post-CAE | 3.8 ± 0.57 | 3.7 ± 0.81 | 4.0 ± 0.74 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 0.9 ± 0.82 | 1.0 ± 1.11 | 1.2 ± 0.92 |
| Change from Baseline: Day 8 | -0.3 ± 0.97 | 0.0 ± 0.98 | -0.2 ± 0.90 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.4 ± 0.93 | 0.0 ± 1.00 | -0.1 ± 0.97 |
| Change from Baseline: Day 15 (Post-CAE) | -0.2 ± 0.78 | 0.0 ± 0.66 | -0.2 ± 0.95 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | 0.2 ± 1.13 | 0.0 ± 1.07 | 0.0 ± 1.40 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.3 ± 1.05 | -0.3 ± 1.19 | -0.3 ± 1.17 |
| Change from Baseline: Day 29 (Post-CAE) | -0.1 ± 0.90 | 0.0 ± 0.89 | -0.1 ± 0.72 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | 0.3 ± 1.03 | 0.3 ± 1.23 | 0.2 ± 1.49 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.5 ± 1.35 | -0.4 ± 1.35 | -0.2 ± 1.06 |
| Change from Baseline: Day 57 (Post-CAE) | -0.2 ± 0.86 | 0.0 ± 0.64 | -0.4 ± 0.98 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | 0.3 ± 1.47 | 0.5 ± 1.32 | -0.1 ± 1.33 |
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of burning at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 1.6 ± 1.31 | 1.4 ± 1.35 | 1.2 ± 1.28 |
| Day 1 Post-CAE | 2.5 ± 1.49 | 2.3 ± 1.55 | 2.4 ± 1.66 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 1.0 ± 1.26 | 0.9 ± 1.12 | 1.2 ± 1.29 |
| Change from Baseline: Day 8 | -0.1 ± 0.81 | 0.0 ± 0.92 | 0.0 ± 0.85 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.1 ± 1.04 | -0.2 ± 1.14 | 0.0 ± 0.74 |
| Change from Baseline: Day 15 (Post-CAE) | -0.1 ± 1.16 | 0.0 ± 1.17 | -0.1 ± 1.05 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | 0.0 ± 1.62 | 0.2 ± 1.40 | -0.1 ± 1.40 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.1 ± 1.14 | -0.2 ± 1.18 | 0.0 ± 0.84 |
| Change from Baseline: Day 29 (Post-CAE) | -0.1 ± 1.35 | -0.2 ± 0.97 | -0.1 ± 0.85 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | 0.1 ± 1.25 | 0.4 ± 1.24 | -0.3 ± 1.21 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.1 ± 1.22 | -0.5 ± 1.50 | -0.1 ± 0.93 |
| Change from Baseline: Day 57 (Post-CAE) | -0.2 ± 1.09 | -0.1 ± 1.28 | -0.3 ± 1.01 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -0.1 ± 1.48 | 0.5 ± 1.26 | -0.2 ± 1.30 |
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of dryness at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 3.1 ± 0.87 | 3.1 ± 1.03 | 3.0 ± 0.84 |
| Day 1 Post-CAE | 4.0 ± 0.71 | 3.9 ± 0.80 | 4.1 ± 0.63 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 1.0 ± 0.86 | 0.9 ± 0.76 | 1.1 ± 0.99 |
| Change from Baseline: Day 8 | -0.4 ± 0.90 | -0.1 ± 0.70 | -0.2 ± 0.77 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.3 ± 0.80 | -0.2 ± 0.90 | -0.1 ± 0.76 |
| Change from Baseline: Day 15 (Post-CAE) | -0.2 ± 0.71 | -0.2 ± 0.80 | -0.1 ± 0.95 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | 0.1 ± 1.08 | 0.0 ± 0.98 | 0.0 ± 1.29 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.2 ± 1.03 | -0.4 ± 1.01 | -0.3 ± 0.94 |
| Change from Baseline: Day 29 (Post-CAE) | -0.3 ± 1.04 | -0.2 ± 0.67 | -0.2 ± 0.79 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | 0.0 ± 0.98 | 0.5 ± 1.17 | 0.1 ± 1.33 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.4 ± 1.25 | -0.3 ± 1.20 | -0.2 ± 1.08 |
| Change from Baseline: Day 57 (Post-CAE) | -0.2 ± 0.85 | -0.1 ± 0.82 | -0.3 ± 1.09 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | 0.1 ± 1.31 | 0.3 ± 1.04 | -0.1 ± 1.36 |
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of grittiness at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 2.1 ± 1.27 | 1.8 ± 1.47 | 2.0 ± 1.35 |
| Day 1 Post-CAE | 2.7 ± 1.40 | 2.3 ± 1.63 | 3.0 ± 1.28 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 0.7 ± 1.10 | 0.5 ± 0.96 | 1.1 ± 1.10 |
| Change from Baseline: Day 8 | -0.2 ± 1.06 | -0.1 ± 0.67 | 0.1 ± 0.95 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.1 ± 1.05 | 0.2 ± 1.06 | 0.0 ± 0.68 |
| Change from Baseline: Day 15 (Post-CAE) | -0.1 ± 1.00 | 0.2 ± 1.24 | -0.3 ± 1.07 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | 0.0 ± 1.29 | 0.0 ± 1.03 | -0.3 ± 1.33 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.2 ± 1.25 | -0.1 ± 1.18 | -0.2 ± 1.04 |
| Change from Baseline: Day 29 (Post-CAE) | -0.2 ± 0.99 | 0.1 ± 1.03 | -0.1 ± 0.74 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | 0.1 ± 1.18 | 0.3 ± 1.01 | 0.0 ± 1.22 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.4 ± 1.20 | -0.1 ± 1.29 | -0.1 ± 0.94 |
| Change from Baseline: Day 57 (Post-CAE) | -0.3 ± 1.06 | 0.2 ± 1.13 | -0.6 ± 1.08 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | 0.0 ± 1.44 | 0.3 ± 1.09 | -0.4 ± 1.14 |
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of stinging at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 1.5 ± 1.33 | 1.2 ± 1.35 | 1.0 ± 1.08 |
| Day 1 Post-CAE | 2.3 ± 1.42 | 1.9 ± 1.55 | 2.0 ± 1.67 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 0.8 ± 1.18 | 0.7 ± 1.05 | 1.0 ± 1.26 |
| Change from Baseline: Day 8 | -0.3 ± 0.92 | -0.2 ± 0.86 | -0.1 ± 0.69 |
| Change from Baseline: Day 15 (Pre-CAE) | -0.2 ± 1.04 | -0.2 ± 1.08 | 0.0 ± 0.76 |
| Change from Baseline: Day 15 (Post-CAE) | -0.3 ± 1.12 | 0.0 ± 1.00 | -0.1 ± 1.19 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | 0.0 ± 1.34 | 0.2 ± 1.24 | -0.1 ± 1.41 |
| Change from Baseline: Day 29 (Pre-CAE) | -0.2 ± 1.12 | -0.3 ± 1.03 | -0.1 ± 0.90 |
| Change from Baseline: Day 29 (Post-CAE) | -0.3 ± 1.23 | -0.4 ± 1.06 | -0.2 ± 1.28 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | 0.0 ± 1.16 | 0.1 ± 1.06 | -0.2 ± 1.47 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.2 ± 1.35 | -0.3 ± 1.40 | -0.1 ± 1.01 |
| Change from Baseline: Day 57 (Post-CAE) | -0.3 ± 1.12 | -0.1 ± 1.28 | -0.4 ± 1.30 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | 0.0 ± 1.83 | 0.3 ± 1.41 | -0.3 ± 1.51 |
Participants rated ocular symptom of burning by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."
| mm | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 30.4 ± 28.53 | 29.3 ± 26.74 | 22.4 ± 24.60 |
| Day 1 Post-CAE | 44.6 ± 29.99 | 44.1 ± 33.91 | 40.1 ± 32.15 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 14.2 ± 23.57 | 14.5 ± 22.27 | 17.7 ± 22.75 |
| Change from Baseline: Day 8 | -1.9 ± 19.34 | -4.5 ± 25.73 | 0.5 ± 16.66 |
| Change from Baseline: Day 15 (Pre-CAE) | -3.0 ± 19.75 | -6.7 ± 24.08 | 0.3 ± 11.84 |
| Change from Baseline: Day 15 (Post-CAE) | -1.6 ± 23.56 | -10.8 ± 24.27 | -2.2 ± 16.90 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | 1.4 ± 26.91 | -3.5 ± 21.46 | -2.6 ± 17.42 |
| Change from Baseline: Day 29 (Pre-CAE) | -3.0 ± 26.13 | -6.6 ± 26.82 | -0.4 ± 15.67 |
| Change from Baseline: Day 29 (Post-CAE) | -7.3 ± 21.43 | -8.8 ± 26.93 | -3.2 ± 16.00 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -0.2 ± 23.76 | 2.4 ± 25.72 | -4.0 ± 24.77 |
| Change from Baseline: Day 57 (Pre-CAE) | -3.5 ± 27.19 | -10.0 ± 31.76 | -1.5 ± 16.19 |
| Change from Baseline: Day 57 (Post-CAE) | -1.3 ± 20.26 | -10.3 ± 26.98 | -4.6 ± 21.47 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | 2.2 ± 33.08 | 2.2 ± 30.19 | -3.0 ± 23.35 |
Participants rated ocular symptom of itching by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."
| mm | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 28.6 ± 27.09 | 26.2 ± 29.26 | 26.8 ± 23.70 |
| Day 1 Post-CAE | 37.0 ± 30.45 | 31.9 ± 33.26 | 35.0 ± 28.92 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 8.4 ± 21.67 | 5.2 ± 18.00 | 8.2 ± 22.76 |
| Change from Baseline: Day 8 | -6.0 ± 19.05 | -2.8 ± 22.23 | 0.5 ± 19.54 |
| Change from Baseline: Day 15 (Pre-CAE) | -3.1 ± 19.18 | -4.5 ± 18.28 | 1.6 ± 20.27 |
| Change from Baseline: Day 15 (Post-CAE) | -8.0 ± 22.37 | -2.4 ± 19.21 | 1.9 ± 16.56 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -4.9 ± 27.23 | 2.2 ± 21.18 | 0.3 ± 19.52 |
| Change from Baseline: Day 29 (Pre-CAE) | -2.7 ± 24.78 | -9.5 ± 20.74 | -1.7 ± 20.97 |
| Change from Baseline: Day 29 (Post-CAE) | -9.3 ± 19.47 | -6.2 ± 23.64 | 2.2 ± 23.30 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -3.6 ± 15.78 | 5.2 ± 26.67 | 3.6 ± 25.99 |
| Change from Baseline: Day 57 (Pre-CAE) | -6.8 ± 22.73 | -8.1 ± 27.02 | -1.2 ± 23.65 |
| Change from Baseline: Day 57 (Post-CAE) | -7.0 ± 27.35 | -5.7 ± 23.95 | -2.1 ± 19.13 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -0.2 ± 25.65 | 4.7 ± 22.75 | 0.2 ± 26.94 |
Participants rated ocular symptom of foreign body by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."
| mm | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 35.3 ± 25.95 | 35.1 ± 29.19 | 34.1 ± 25.87 |
| Day 1 Post-CAE | 45.1 ± 29.54 | 43.1 ± 31.03 | 49.9 ± 27.82 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 9.8 ± 24.25 | 8.1 ± 22.30 | 15.8 ± 21.57 |
| Change from Baseline: Day 8 | -6.2 ± 23.33 | -3.4 ± 16.32 | -0.4 ± 19.69 |
| Change from Baseline: Day 15 (Pre-CAE) | -7.8 ± 23.00 | -1.3 ± 18.83 | -5.0 ± 17.15 |
| Change from Baseline: Day 15 (Post-CAE) | -8.5 ± 20.45 | -0.7 ± 21.90 | -7.9 ± 18.96 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -0.6 ± 28.16 | 0.8 ± 27.76 | -2.8 ± 20.72 |
| Change from Baseline: Day 29 (Pre-CAE) | -6.2 ± 28.69 | -5.0 ± 16.97 | -5.9 ± 26.37 |
| Change from Baseline: Day 29 (Post-CAE) | -8.6 ± 16.41 | -4.7 ± 19.58 | -1.1 ± 20.54 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | 1.4 ± 19.18 | 2.6 ± 19.77 | -0.6 ± 22.53 |
| Change from Baseline: Day 57 (Pre-CAE) | -9.3 ± 21.64 | -7.3 ± 28.49 | -5.2 ± 18.58 |
| Change from Baseline: Day 57 (Post-CAE) | -10.3 ± 23.81 | -1.5 ± 27.06 | -8.5 ± 19.20 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -1.0 ± 27.77 | 6.9 ± 30.44 | -3.7 ± 25.32 |
Participants rated ocular symptom of blurred vision by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."
| mm | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 18.5 ± 22.85 | 24.0 ± 27.00 | 26.9 ± 20.32 |
| Day 1 Post-CAE | 26.4 ± 28.30 | 32.2 ± 30.82 | 41.1 ± 28.62 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 7.9 ± 18.33 | 8.2 ± 25.15 | 14.2 ± 20.98 |
| Change from Baseline: Day 8 | 2.5 ± 12.34 | -4.5 ± 23.77 | -4.2 ± 15.37 |
| Change from Baseline: Day 15 (Pre-CAE) | 3.7 ± 11.94 | -2.9 ± 19.40 | -2.1 ± 15.80 |
| Change from Baseline: Day 15 (Post-CAE) | -1.1 ± 14.37 | -7.3 ± 24.44 | -8.7 ± 21.87 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -4.7 ± 16.88 | -4.4 ± 23.96 | -6.6 ± 27.55 |
| Change from Baseline: Day 29 (Pre-CAE) | -2.0 ± 14.81 | -4.0 ± 18.45 | -3.2 ± 16.29 |
| Change from Baseline: Day 29 (Post-CAE) | -5.9 ± 16.34 | -7.9 ± 23.39 | -6.1 ± 17.73 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -2.5 ± 19.24 | -5.4 ± 21.62 | -7.7 ± 21.60 |
| Change from Baseline: Day 57 (Pre-CAE) | 0.5 ± 14.90 | -3.0 ± 21.79 | -1.2 ± 19.67 |
| Change from Baseline: Day 57 (Post-CAE) | -4.0 ± 19.15 | -6.9 ± 24.83 | -7.8 ± 21.29 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -4.5 ± 17.82 | -3.3 ± 27.89 | -6.5 ± 27.14 |
Participants rated ocular symptom of dryness by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."
| mm | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 57.7 ± 20.98 | 58.6 ± 24.58 | 58.0 ± 22.90 |
| Day 1 Post-CAE | 74.2 ± 18.66 | 71.8 ± 21.47 | 75.0 ± 18.09 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 16.5 ± 16.76 | 13.3 ± 17.80 | 17.0 ± 18.30 |
| Change from Baseline: Day 8 | -4.7 ± 16.31 | -2.1 ± 14.26 | -1.6 ± 19.15 |
| Change from Baseline: Day 15 (Pre-CAE) | -6.7 ± 19.32 | -7.4 ± 17.94 | -4.2 ± 20.52 |
| Change from Baseline: Day 15 (Post-CAE) | -1.7 ± 12.82 | -4.5 ± 16.69 | -1.7 ± 17.81 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | 5.0 ± 21.30 | 3.0 ± 21.22 | 2.5 ± 22.67 |
| Change from Baseline: Day 29 (Pre-CAE) | -6.4 ± 23.40 | -10.3 ± 19.89 | -7.1 ± 25.61 |
| Change from Baseline: Day 29 (Post-CAE) | -5.8 ± 14.15 | -7.1 ± 13.36 | -5.1 ± 12.50 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | 2.3 ± 21.34 | 3.5 ± 20.86 | 0.6 ± 23.70 |
| Change from Baseline: Day 57 (Pre-CAE) | -11.7 ± 24.14 | -11.3 ± 26.02 | -8.4 ± 26.81 |
| Change from Baseline: Day 57 (Post-CAE) | -8.3 ± 15.28 | -3.8 ± 14.57 | -7.7 ± 22.21 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | 3.3 ± 25.71 | 9.0 ± 24.83 | 1.7 ± 25.52 |
Participants rated ocular symptom of photophobia by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."
| mm | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 32.8 ± 28.41 | 37.4 ± 33.86 | 36.7 ± 29.19 |
| Day 1 Post-CAE | 38.1 ± 29.80 | 39.8 ± 34.50 | 49.7 ± 32.33 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 5.3 ± 16.70 | 2.2 ± 21.20 | 13.0 ± 22.01 |
| Change from Baseline: Day 8 | 1.4 ± 16.17 | -5.0 ± 21.40 | -2.7 ± 18.46 |
| Change from Baseline: Day 15 (Pre-CAE) | -1.4 ± 16.19 | -11.0 ± 22.36 | -2.1 ± 18.17 |
| Change from Baseline: Day 15 (Post-CAE) | -2.4 ± 14.21 | -5.7 ± 19.94 | -8.8 ± 18.47 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -1.0 ± 19.59 | 5.8 ± 23.32 | -6.7 ± 22.12 |
| Change from Baseline: Day 29 (Pre-CAE) | -3.1 ± 19.61 | -7.3 ± 28.18 | -3.1 ± 26.01 |
| Change from Baseline: Day 29 (Post-CAE) | -4.0 ± 13.84 | -4.9 ± 18.11 | -0.9 ± 18.18 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | 3.0 ± 17.38 | 2.1 ± 13.89 | -2.7 ± 27.46 |
| Change from Baseline: Day 57 (Pre-CAE) | -4.1 ± 20.87 | -3.6 ± 26.95 | -3.6 ± 22.33 |
| Change from Baseline: Day 57 (Post-CAE) | -4.0 ± 21.66 | -2.3 ± 20.85 | -10.4 ± 23.91 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | 0.2 ± 28.34 | 1.5 ± 21.40 | -6.5 ± 24.53 |
Participants rated ocular symptom of pain by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."
| mm | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 Pre-CAE | 17.0 ± 22.31 | 17.8 ± 23.62 | 17.4 ± 21.01 |
| Day 1 Post-CAE | 29.1 ± 30.50 | 26.3 ± 29.53 | 27.1 ± 29.83 |
| Day 1 (Change from Pre-CAE to Post-CAE) | 12.1 ± 19.65 | 8.3 ± 15.81 | 9.7 ± 20.73 |
| Change from Baseline: Day 8 | -2.2 ± 11.94 | -1.8 ± 22.41 | -2.6 ± 13.91 |
| Change from Baseline: Day 15 (Pre-CAE) | 1.8 ± 20.34 | -3.1 ± 22.90 | -2.1 ± 14.54 |
| Change from Baseline: Day 15 (Post-CAE) | -3.9 ± 17.59 | -2.0 ± 16.84 | -2.8 ± 18.66 |
| Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE) | -5.7 ± 19.81 | 1.5 ± 22.96 | -0.8 ± 23.07 |
| Change from Baseline: Day 29 (Pre-CAE) | -3.8 ± 17.30 | -3.3 ± 20.23 | -3.4 ± 15.35 |
| Change from Baseline: Day 29 (Post-CAE) | -8.0 ± 16.05 | -1.8 ± 18.57 | -9.9 ± 18.61 |
| Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE) | -3.3 ± 15.38 | 7.7 ± 16.05 | -8.1 ± 20.05 |
| Change from Baseline: Day 57 (Pre-CAE) | -0.2 ± 22.85 | -6.6 ± 24.80 | -2.8 ± 14.32 |
| Change from Baseline: Day 57 (Post-CAE) | -10.9 ± 16.16 | -4.1 ± 20.22 | -2.1 ± 12.68 |
| Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE) | -10.7 ± 28.15 | 3.9 ± 21.67 | 0.7 ± 16.52 |
The OSDI is a simple 12-question survey that rates the severity of the participant's dry eye disease based on the symptoms. It is assessed on a scale of 0 to 100, with higher score representing greater disability.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Day 1 | 32.45 ± 14.379 | 36.78 ± 18.209 | 38.08 ± 16.602 |
| Change From Baseline: Day 8 | -1.57 ± 7.885 | -0.87 ± 7.889 | -3.79 ± 8.161 |
| Change From Baseline: Day 15 | -0.49 ± 9.048 | -2.98 ± 10.361 | -3.65 ± 10.727 |
| Change From Baseline: Day 29 | -0.92 ± 10.324 | -4.42 ± 12.540 | -5.48 ± 12.471 |
| Change From Baseline: Day 57 | -1.45 ± 11.598 | -3.33 ± 11.978 | -5.05 ± 10.817 |
Ora Calibra® drop comfort scale ranges from 0 to 10. A score of 0 indicates comfortable and 10 indicates uncomfortable. Lower score indicated better comfort level.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Upon instillation on Day 1 | 2.8 ± 2.25 | 3.6 ± 2.40 | 3.3 ± 2.69 |
| 1 minute post-instillation on Day 1 | 2.0 ± 1.86 | 2.6 ± 1.93 | 2.3 ± 1.84 |
| 2 minutes post-instillation on Day 1 | 1.6 ± 1.75 | 2.3 ± 1.91 | 2.0 ± 1.89 |
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of overall ocular discomfort twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Baseline: Daily average | 2.74 ± 0.884 | 2.82 ± 0.934 | 2.66 ± 0.789 |
| Average Day 1 to Day 7: Change from Baseline Daily Average | -0.13 ± 0.326 | -0.09 ± 0.337 | -0.07 ± 0.376 |
| Average Day 8 to Day 14: Change from Baseline Daily Average | -0.24 ± 0.430 | -0.10 ± 0.442 | -0.09 ± 0.510 |
| Average Day 15 to Day 21: Change from Baseline Daily Average | -0.21 ± 0.534 | -0.19 ± 0.465 | -0.13 ± 0.628 |
| Average Day 22 to Day 28: Change from Baseline Daily Average | -0.23 ± 0.558 | -0.29 ± 0.464 | -0.24 ± 0.650 |
| Average Day 29 to Day 35: Change from Baseline Daily Average | -0.18 ± 0.600 | -0.25 ± 0.548 | -0.15 ± 0.623 |
| Average Day 36 to Day 42: Change from Baseline Daily Average | -0.28 ± 0.597 | -0.28 ± 0.638 | -0.18 ± 0.638 |
| Average Day 43 to Day 49: Change from Baseline Daily Average | -0.34 ± 0.636 | -0.31 ± 0.666 | -0.16 ± 0.662 |
| Average Day 50 to Day 56: Change from Baseline Daily Average | -0.38 ± 0.713 | -0.29 ± 0.658 | -0.16 ± 0.674 |
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of burning twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Baseline: Daily average | 1.72 ± 1.126 | 1.49 ± 1.134 | 1.50 ± 1.135 |
| Average Day 1 to Day 7: Change from Baseline Daily Average | -0.13 ± 0.309 | -0.08 ± 0.398 | -0.07 ± 0.328 |
| Average Day 8 to Day 14: Change from Baseline Daily Average | -0.26 ± 0.369 | -0.17 ± 0.438 | -0.11 ± 0.420 |
| Average Day 15 to Day 21: Change from Baseline Daily Average | -0.22 ± 0.430 | -0.21 ± 0.498 | -0.12 ± 0.464 |
| Average Day 22 to Day 28: Change from Baseline Daily Average | -0.26 ± 0.449 | -0.29 ± 0.511 | -0.18 ± 0.546 |
| Average Day 29 to Day 35: Change from Baseline Daily Average | -0.18 ± 0.506 | -0.28 ± 0.523 | -0.11 ± 0.511 |
| Average Day 36 to Day 42: Change from Baseline Daily Average | -0.25 ± 0.440 | -0.35 ± 0.701 | -0.17 ± 0.500 |
| Average Day 43 to Day 49: Change from Baseline Daily Average | -0.25 ± 0.565 | -0.33 ± 0.647 | -0.13 ± 0.564 |
| Average Day 50 to Day 56: Change from Baseline Daily Average | -0.27 ± 0.571 | -0.33 ± 0.739 | -0.11 ± 0.527 |
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of dryness twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Baseline: Daily average | 2.88 ± 0.793 | 2.96 ± 0.968 | 2.99 ± 0.669 |
| Average Day 1 to Day 7: Change from Baseline Daily Average | -0.13 ± 0.391 | -0.11 ± 0.275 | -0.10 ± 0.383 |
| Average Day 8 to Day 14: Change from Baseline Daily Average | -0.20 ± 0.505 | -0.14 ± 0.388 | -0.13 ± 0.504 |
| Average Day 15 to Day 21: Change from Baseline Daily Average | -0.20 ± 0.615 | -0.25 ± 0.479 | -0.13 ± 0.621 |
| Average Day 22 to Day 28: Change from Baseline Daily Average | -0.23 ± 0.620 | -0.30 ± 0.519 | -0.29 ± 0.659 |
| Average Day 29 to Day 35: Change from Baseline Daily Average | -0.17 ± 0.691 | -0.29 ± 0.485 | -0.21 ± 0.690 |
| Average Day 36 to Day 42: Change from Baseline Daily Average | -0.30 ± 0.680 | -0.32 ± 0.628 | -0.23 ± 0.677 |
| Average Day 43 to Day 49: Change from Baseline Daily Average | -0.35 ± 0.728 | -0.31 ± 0.704 | -0.25 ± 0.768 |
| Average Day 50 to Day 56: Change from Baseline Daily Average | -0.40 ± 0.793 | -0.29 ± 0.703 | -0.27 ± 0.812 |
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of grittiness twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Baseline: Daily average | 2.14 ± 0.988 | 1.84 ± 1.248 | 2.07 ± 1.177 |
| Average Day 1 to Day 7: Change from Baseline Daily Average | -0.19 ± 0.450 | -0.07 ± 0.331 | -0.03 ± 0.407 |
| Average Day 8 to Day 14: Change from Baseline Daily Average | -0.27 ± 0.555 | -0.07 ± 0.500 | -0.08 ± 0.555 |
| Average Day 15 to Day 21: Change from Baseline Daily Average | -0.22 ± 0.594 | -0.16 ± 0.540 | -0.14 ± 0.554 |
| Average Day 22 to Day 28: Change from Baseline Daily Average | -0.26 ± 0.628 | -0.21 ± 0.615 | -0.23 ± 0.655 |
| Average Day 29 to Day 35: Change from Baseline Daily Average | -0.21 ± 0.724 | -0.22 ± 0.554 | -0.18 ± 0.627 |
| Average Day 36 to Day 42: Change from Baseline Daily Average | -0.35 ± 0.682 | -0.18 ± 0.642 | -0.18 ± 0.561 |
| Average Day 43 to Day 49: Change from Baseline Daily Average | -0.38 ± 0.682 | -0.16 ± 0.833 | -0.16 ± 0.666 |
| Average Day 50 to Day 56: Change from Baseline Daily Average | -0.36 ± 0.764 | -0.11 ± 0.959 | -0.18 ± 0.708 |
Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of stinging twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.
| score on a scale | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| Baseline: Daily average | 1.53 ± 1.113 | 1.20 ± 1.127 | 1.26 ± 1.075 |
| Average Day 1 to Day 7: Change from Baseline Daily Average | -0.14 ± 0.349 | -0.13 ± 0.327 | -0.11 ± 0.342 |
| Average Day 8 to Day 14: Change from Baseline Daily Average | -0.24 ± 0.409 | -0.12 ± 0.438 | -0.14 ± 0.469 |
| Average Day 15 to Day 21: Change from Baseline Daily Average | -0.16 ± 0.428 | -0.22 ± 0.515 | -0.20 ± 0.455 |
| Average Day 22 to Day 28: Change from Baseline Daily Average | -0.12 ± 0.517 | -0.28 ± 0.533 | -0.24 ± 0.546 |
| Average Day 29 to Day 35: Change from Baseline Daily Average | -0.11 ± 0.572 | -0.28 ± 0.538 | -0.21 ± 0.517 |
| Average Day 36 to Day 42: Change from Baseline Daily Average | -0.22 ± 0.564 | -0.32 ± 0.631 | -0.20 ± 0.514 |
| Average Day 43 to Day 49: Change from Baseline Daily Average | -0.24 ± 0.553 | -0.27 ± 0.647 | -0.16 ± 0.612 |
| Average Day 50 to Day 56: Change from Baseline Daily Average | -0.22 ± 0.575 | -0.28 ± 0.744 | -0.15 ± 0.577 |
Collected over Baseline up to 8 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.10% HL036 Ophthalmic Solution | 0/50 (0%) | 0/50 (0%) | 13/50 (26%) |
| 0.25% HL036 Ophthalmic Solution | 0/50 (0%) | 0/50 (0%) | 13/50 (26%) |
| Placebo | 0/50 (0%) | 0/50 (0%) | 9/50 (18%) |
| Event | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 5/50 | 3/50 | 8/50 |
| Instillation site painGeneral disorders | 2/50 | 6/50 | 1/50 |
| Conjunctivitis allergicEye disorders | 3/50 | 4/50 | 0/50 |
| Visual acuity reducedEye disorders | 3/50 | 0/50 | 0/50 |
Intent-to-treat (ITT) population: The ITT population included all randomized participants.
| Age, Continuous(years) | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo | Total |
|---|---|---|---|---|
| Mean | 60.9 ± 13.09 | 63.5 ± 9.92 | 66.1 ± 11.38 | 63.5 ± 11.65 |
| Sex: Female, Male(Participants) | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo | Total |
|---|---|---|---|---|
| Female | 30 | 40 | 38 | 108 |
| Male | 20 | 10 | 12 | 42 |
| Ethnicity (NIH/OMB)(Participants) | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 2 | 5 |
| Not Hispanic or Latino | 48 | 49 | 48 | 145 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 0.10% HL036 Ophthalmic Solution | 0.25% HL036 Ophthalmic Solution | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 |
| White | 49 | 48 | 48 | 145 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in Apr 2018, 5 months.
Results were first posted in Jan 2022, 3 years 9 months after primary completion.
Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 5 months is below that.
Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tanfanercept